- Report
- January 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- February 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- September 2023
- 180 Pages
Global
From €5733EUR$5,950USD£4,932GBP
- Report
- March 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- January 2024
- 190 Pages
Global
From €4722EUR$4,900USD£4,061GBP
- Report
- November 2023
- 182 Pages
Global
From €4722EUR$4,900USD£4,061GBP
- Report
- September 2023
- 173 Pages
Global
From €3069EUR$3,185USD£2,640GBP
€4384EUR$4,550USD£3,771GBP
- Report
- January 2024
- 323 Pages
Global
€4813EUR$4,995USD£4,140GBP
- Report
- July 2023
- 104 Pages
North America
From €1445EUR$1,500USD£1,243GBP
- Report
- July 2022
- 155 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Report
- January 2022
- 200 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Report
- February 2024
- 91 Pages
From €3421EUR$3,550USD£2,942GBP
- Clinical Trials
- October 2021
- 121 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Report
- March 2021
- 49 Pages
Global
From €3368EUR$3,495USD£2,897GBP
- Clinical Trials
- October 2020
- 111 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Clinical Trials
- October 2020
- 118 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Clinical Trials
- July 2020
- 247 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Report
- May 2023
- 85 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Report
- February 2024
- 180 Pages
Global
From €5299EUR$5,499USD£4,558GBP
- Book
- March 2014
- 144 Pages
Retinal Vein Occlusion (RVO) is a condition in which the veins in the retina become blocked, leading to vision loss. It is the second most common cause of vision loss in the elderly, and is often caused by hypertension, diabetes, and other vascular diseases. Treatment for RVO includes laser photocoagulation, intravitreal injections, and vitrectomy. Optical treatments such as optical coherence tomography (OCT) and fundus photography are used to diagnose and monitor the condition.
In the RVO market, companies such as Carl Zeiss Meditec, Topcon Corporation, Heidelberg Engineering, Optovue, and Nidek Co. Ltd. are involved in the development and manufacture of optical imaging systems and treatments for RVO. These companies provide a range of products and services, including OCT systems, fundus cameras, laser photocoagulation systems, and intravitreal injections. Show Less Read more